You are here: Home » Companies » Industry
Business Standard

200 'high-risk' drug firms come under Indian regulator lens

Centre, states jointly assess drug manufacturers' facilities

Veena Mani & Aneesh Phadnis  |  New Delhi/ Mumbai 

The Central Drugs Standard Control Organization (CDSCO) is learnt to have classified more than 200 pharmaceutical companies as high-risk, in a first such move to cleanse the Indian pharmaceutical sector. CDSCO officials refused to divulge the names. Sources said the Indian authorities have taken a decision to follow the model of the US regulator (US Food and Drug Administration, or USFDA) in cracking down on pharma companies violating compliance norms. This is also for the first time that CDSCO has joined hands with state regulators to conduct risk-based assessments of pharma ...

TO READ THE FULL STORY, SUBSCRIBE NOW AT JUST Rs 149 A MONTH

Key stories on business-standard.com are available to premium subscribers only.

LOGIN

EMAIL / USER NAME
PASSWORD
REMEMBER ME Forgot password?

Not a member yet ? Resister Now

Connect using any below

  • Don't lose the opportunity of saving $26.77 per month
  • Don't lose the opportunity of saving $26.77 per month
Total Amount
Rs. 0.00
To proceed, kindly select a subscription package

WHAT YOU GET

On Business Standard Digital

  • Access your subscription from anywhere. Be it your computer, tablet or smartphone using a browser or the App, Your Choice.
  • Access to exclusive content, features, opinions and comment, hand-picked by our editors, just for you.
  • Pick your 5 favourite companies. Get all the news upates at the end of each day through E-Mail.
  • Pick the industry that you want to track. And get a daily news letter specific to that industry. Cut out the clutter.
  • And stay on top of your investments. Track stock prices in your portfolio
  • Access 18 years of archival data

On Digital

  • Seamless access to WSJ.com with your Business Standard digital account.
  • Experience the best of the Journal's reporting, video and interactive features.
  • Read about the people and events shaping business, finance, technology, politics, technology and culture.
  • Stay informed with newsletters - an easy way to get WSJ content straight to your inbox - making life easier on your busiest days.
  • More business executives read the Journal globally than any other publication.
*Note :
American Express® is proud to be associated with this initiative and will contribute Rs 100 x 6 months thereafter, standard rate of Rs 149 will be charged.
Offer valid for Indian residents only
Requires you to share personal information like PAN, Date of Birth, and Income.
*Annual saving on WSJ subscription price of US$ 347.88 (12 months @ US$ 28.99 per month)
* 1US$ = 67.50 INR.
*Please note that this offer is not valid if you are/were a registered/existing user on WSJ Digital
RECOMMENDED FOR YOU

200 'high-risk' drug firms come under Indian regulator lens

Centre, states jointly assess drug manufacturers' facilities

Centre, states jointly assess drug manufacturers' facilities The Central Drugs Standard Control Organization (CDSCO) is learnt to have classified more than 200 pharmaceutical companies as high-risk, in a first such move to cleanse the Indian pharmaceutical sector. CDSCO officials refused to divulge the names. Sources said the Indian authorities have taken a decision to follow the model of the US regulator (US Food and Drug Administration, or USFDA) in cracking down on pharma companies violating compliance norms. This is also for the first time that CDSCO has joined hands with state regulators to conduct risk-based assessments of pharma ... image
Business Standard
177 22

200 'high-risk' drug firms come under Indian regulator lens

Centre, states jointly assess drug manufacturers' facilities

The Central Drugs Standard Control Organization (CDSCO) is learnt to have classified more than 200 pharmaceutical companies as high-risk, in a first such move to cleanse the Indian pharmaceutical sector. CDSCO officials refused to divulge the names. Sources said the Indian authorities have taken a decision to follow the model of the US regulator (US Food and Drug Administration, or USFDA) in cracking down on pharma companies violating compliance norms. This is also for the first time that CDSCO has joined hands with state regulators to conduct risk-based assessments of pharma ...

image
Business Standard
177 22

Upgrade To Premium Services

Welcome User

Business Standard is happy to inform you of the launch of "Business Standard Premium Services"

As a premium subscriber you get an across device unfettered access to a range of services which include:

  • Access Exclusive content - articles, features & opinion pieces
  • Weekly Industry/Genre specific newsletters - Choose multiple industries/genres
  • Access to 17 plus years of content archives
  • Set Stock price alerts for your portfolio and watch list and get them delivered to your e-mail box
  • End of day news alerts on 5 companies (via email)
  • NEW: Get seamless access to WSJ.com at a great price. No additional sign-up required.
 

Premium Services

In Partnership with

 

Dear Guest,

 

Welcome to the premium services of Business Standard brought to you courtesy FIS.
Kindly visit the Manage my subscription page to discover the benefits of this programme.

Enjoy Reading!
Team Business Standard